Flagship Pioneering led a $189m Series B round in Repertoire Immune Medicines.

Flagship Pioneering led a $189m Series B round in Repertoire Immune Medicines, a clinical-stage biotech company, with participation from Softbank Vision Fund 2, PSP Investments, Alaska Permanent Fund and Invus. Proceeds from this financing will support further expansion of the company’s proprietary DECODE discovery platform, accelerate its clinical and preclinical pipeline, expand Repertoire’s team, and enhance its manufacturing capabilities.